Ignite Creation Date:
2024-05-06 @ 3:46 AM
Last Modification Date:
2024-10-26 @ 11:38 AM
Study NCT ID:
NCT02367638
Status:
COMPLETED
Last Update Posted:
2017-04-27
First Post:
2015-02-12
Brief Title:
Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
A Single-center Dose Block-randomized Single-blind Active-controlled Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy Immunogenicity of MG1111 in Healthy Adults
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None